Wordt geladen...
Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging
BACKGROUND: De novo or acquired resistance in breast cancer leads to treatment failures and disease progression. In human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer, Src, a non-receptor tyrosine kinase, is identified as a major mechanism of trastuzumab resistance, with...
Bewaard in:
| Gepubliceerd in: | Breast Cancer Res |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6203283/ https://ncbi.nlm.nih.gov/pubmed/30359299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-018-1055-2 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|